Allogene Therapeutics Inc (NASDAQ: ALLO) on Tuesday, plunged -7.48% from the previous trading day, before settling in for the closing price of $1.47. Within the past 52 weeks, ALLO’s price has moved between $0.86 and $3.78.
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.26%. The company achieved an average annual earnings per share of 29.47%. With a float of $160.27 million, this company’s outstanding shares have now reached $223.16 million.
Let’s determine the extent of company efficiency that accounts for 229 employees.
Allogene Therapeutics Inc (ALLO) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Allogene Therapeutics Inc is 28.68%, while institutional ownership is 50.55%. The most recent insider transaction that took place on Nov 17 ’25, was worth 959. In this transaction SVP, Chief Technical Officer of this company sold 786 shares at a rate of $1.22, taking the stock ownership to the 217,721 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 786 for $1.22, making the entire transaction worth $959.
Allogene Therapeutics Inc (ALLO) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.28 earnings per share (EPS) for the period topping the consensus outlook (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.61% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Allogene Therapeutics Inc (ALLO) is currently performing well based on its current performance indicators. A quick ratio of 8.19 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Looking closely at Allogene Therapeutics Inc (NASDAQ: ALLO), its last 5-days average volume was 3.4 million, which is a drop from its year-to-date volume of 3.85 million. As of the previous 9 days, the stock’s Stochastic %D was 28.87%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 64.70%, which indicates a significant increase from 16.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0983 in the past 14 days, which was higher than the 0.0849 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3102, while its 200-day Moving Average is $1.3104. However, in the short run, Allogene Therapeutics Inc’s stock first resistance to watch stands at $1.4400. Second resistance stands at $1.5200. The third major resistance level sits at $1.5800. If the price goes on to break the first support level at $1.3000, it is likely to go to the next support level at $1.2400. Now, if the price goes above the second support level, the third support stands at $1.1600.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
Market capitalization of the company is 305.63 million based on 224,730K outstanding shares. Right now, sales total 20 K and income totals -257,590 K. The company made 0 K in profit during its latest quarter, and -41,400 K in sales during its previous quarter.
